

Reply to
Before scoliosis can be attributed to the variant c.326G>A in MYH3, its pathogenicity must be proven

Maria Chiara Maccarone,^{1,2} Matilde Paramento,^{1,3} Edoardo Passarotto,¹ Paola Contessa,⁴ Maria Rubega,¹ Emanuela Formaggio,¹ Stefano Masiero^{1,4}

¹Department of Neurosciences, Section of Rehabilitation, University of Padova, Italy; ²Padova Neuroscience Center, University of Padova, Italy; ³Department of Information Engineering, University of Padova, Italy; ⁴Orthopedic Rehabilitation Unit, Padova University Hospital, Padova, Italy.

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Key Words: MYH3, scoliosis, genetic testing, Freeman-Sheldon syndrome, Sheldon Hall syndrome.

Eur J Transl Myol 35 (3) 14034, 2025 doi: 10.4081/ejtm.2025.14034

Dear Editor,

We appreciate the valuable comments regarding our recent case report on a 15-year-old girl presenting with scoliosis, growth retardation, facial dysmorphism, and delayed puberty, who was found to carry the heterozygous NM_002470.4(MYH3):c.326G>A (p.Arg109His) variant.¹ We welcome the opportunity to address the concerns raised and to further clarify aspects of our study, as constructive scientific dialogue is important for refining our understanding of the pathophysiology of scoliosis.

We acknowledge that the pathogenicity of the genetic variant has not been definitively established. MYH3 variants have been implicated in a variety of phenotypic presentations, ranging from severe congenital syndromes to milder musculoskeletal abnormalities.^{2,3} Our patient exhibited subtle facial dysmorphism and musculoskeletal abnormalities. She did not present any additional dysmorphic features beyond those described in our report. Given her unusual phenotype, the diagnosis was even more challenging, and this may be one of the reasons why a diagnosis was made at age 15. Our case study contributes to expanding the known clinical spectrum and raises the possibility that this specific variant may have incomplete penetrance or variable expressivity. Importantly, our work does not suggest a causal relation between the MYH3 variant and rapidly progressing scoliosis, but it raises the possibility that scoliosis may be one of the clinical presentations of the disease. Therefore, we suggest that a rapidly developing scoliosis, coupled with other relevant clinical signs, should be taken into account as a possible indicator of syndromes that require additional investigation.^{4,5}

No information on first-degree relatives or on the clinical history of the patient are reported in the original work be-

cause the primary objective of our case report is to highlight how a musculoskeletal deformity, such as scoliosis, may serve as a clinical marker of underlying pathological conditions warranting further investigation, rather than to provide a complete characterization of this specific case of MYH3 variant. The patient was referred to our rehabilitation service at the University Hospital of Padua due to rapidly progressing scoliosis. As part of a broader study investigating idiopathic scoliosis, a neurophysiological assessment was conducted, allowing for a more comprehensive evaluation of the patient's condition.⁵ This initial assessment prompted additional investigations, including genetic testing, thereby discovering the genetic variant. No genetic testing was done earlier because (we can only assume since the patient was followed elsewhere) the patient presented with subtle manifestations that had never been further investigated before our evaluation for musculoskeletal deformity. Although earlier testing might have been beneficial, the patient's initial clinical features were not immediately suggestive of a known syndromic condition. Nonetheless, we are happy to address the reviewer's concerns by reporting that both the mother and grandmother carried the same MYH3 variant but exhibited only mild musculoskeletal manifestations, without scoliosis or significant dysmorphism. Other first-degree relatives were unavailable for genetic testing.

While it would indeed be interesting to investigate or rule out additional chromosomal defects in conjunction with the MYH3 variant, this is outside of the scope of our investigation, which focuses on reporting the specific musculoskeletal manifestations and correlation with EEG activation in the patient. These future assessments fall outside the scope of our case report.

Cardiac and pulmonary assessments, including echocardiography and pulmonary function tests, were within nor-

Reply to: *MYH3 mutation and scoliosis*

Eur J Transl Myol 35 (3) 14034, 2025 doi: 10.4081/ejtm.2025.14034

mal limits at the time of evaluation. However, given the potential for scoliosis progression to affect cardiopulmonary function, long-term follow-up remains essential. Additionally, considering the role of MYH3 in muscle function, further studies could explore whether this variant might contribute to neuromuscular dysfunction affecting respiration or cardiovascular health.³

Finally, we acknowledge that the interpretation of EEG spectral analysis in scoliosis remains an emerging area of research.⁶ While our findings suggest altered sensorimotor processing, further studies are needed to validate EEG as a reliable biomarker in the pathophysiology of scoliosis.^{5,6} Specifically, prospective studies comparing EEG spectral analysis in scoliosis patients versus controls, along with additional neurophysiological and biomechanical assessments, could provide more robust evidence regarding the potential role of altered cortical activity in the pathogenesis of scoliosis.

In conclusion, this case highlights the importance of thorough evaluations in patients with atypical musculoskeletal presentations, as scoliosis may be an early marker of underlying conditions requiring further investigation. We hope our response provides clarity and contributes to an ongoing discussion on this topic.

List of abbreviations

AIS, Adolescent Idiopathic Scoliosis
EEG, Electroencephalography

Funding statement

The study was supported by Fondazione Cassa di Risparmio di Padova e Rovigo (MP); REACT EU—PON «Ricerca e Innovazione» 2014–2020, DM 1062/2021 (MR); PRIN2022DM104 under Grant 2022MMNCKC (SM, EP).

Conflict of interest

The authors declare no conflicts of interest.

Ethics approval

All methods were carried out in accordance with the guidelines of the 2008 Helsinki Declaration. Ethical approval was obtained in April 2023 (5627/AO/22).

Availability of data and materials

All data generated or analyzed during this study can be provided upon request.

Contributions

SM and EF, Development of the study design, supervision, MCM, MP, EP, PC, MR, and EF, data collection, data interpretation, MCM, MR, and EF, writing, MCM, MR, and EF, data analysis.

Informed consent

All patients participating in this study signed a written informed consent form.

Corresponding author

Maria Chiara Maccarone, Department of Neurosciences, Section of Rehabilitation, University of Padova, via Giustiniani 2, 35128 Padova, Italy.
ORCID ID: 0000-0003-2793-1334
E-mail: mariachiara.maccarone@phd.unipd.it

Co-authors

Matilde Paramento
ORCID: 0000-0002-3268-0309
E-mail: matilde.paramento@phd.unipd.it

Edoardo Passarotto
ORCID ID: 0000-0001-7653-9377
E-mail: edoardo.passarotto@studenti.unipd.it

Paola Contessa
ORCID ID: 0000-0002-8645-6783
E-mail: paola.contessa@aopd.veneto.it

Maria Rubega
ORCID ID: 0000-0002-0744-3109
E-mail: maria.rubega@unipd.it

Emanuela Formaggio
ORCID ID: 0000-0002-3417-0388
E-mail: emanuela.formaggio@unipd.it

Stefano Masiero
ORCID ID: 0000-0002-0361-4898
E-mail: stef.masiero@unipd.it

References

1. Maccarone MC, Paramento M, Passarotto E, et al. A neurophysiological and genetic assessment of a case of rapidly progressive scoliosis. *Eur J Transl Myol* 2024;35:13249.
2. Yang Y, Zhang W, Wang H. Identification of two novel MYH3 variants causing different phenotypes in prenatal diagnosis. *Prenat Diagn* 2023;43:1467-71.
3. Zhao S, Zhang Y, Hallgrimsdottir S, et al. Expanding the mutation and phenotype spectrum of MYH3-associated skeletal disorders. *NPJ Genom Med* 2022;7:1.
4. Maccarone MC, Barzizza E, Contessa P, et al. Lessons from the pandemic era: do we need new strategies to improve conservative treatment adherence in adolescent idiopathic scoliosis? A retrospective analysis. *Eur J Transl Myol* 2024;34:12859.
5. Paramento M, Rubega M, Di Marco R, et al. Experimental protocol to investigate cortical, muscular and body representation alterations in adolescents with idiopathic scoliosis. *PLoS One* 2023;18:e0292864.

Reply to: *MYH3 mutation and scoliosis*

Eur J Transl Myol 35 (3) 14034, 2025 doi: 10.4081/ejtm.2025.14034

6. Paramento M, Passarotto E, Maccarone MC, et al. Neurophysiological, balance and motion evidence in adolescent idiopathic scoliosis: A systematic review. PLoS One 2024;19:e0303086.

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Submitted: 27 May 2025.

Accepted: 27 May 2025.

Early access: 27 June 2025.